Annual Cash & Cash Equivalents
$22.56 M
+$1.36 M+6.43%
December 1, 2024
Summary
- As of March 13, 2025, DSGN annual cash & cash equivalents is $22.56 million, with the most recent change of +$1.36 million (+6.43%) on December 1, 2024.
- During the last 3 years, DSGN annual cash & cash equivalents has fallen by -$276.01 million (-92.44%).
- DSGN annual cash & cash equivalents is now -92.44% below its all-time high of $298.57 million, reached on December 31, 2021.
Performance
DSGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$22.56 M
-$7.76 M-25.60%
December 1, 2024
Summary
- As of March 13, 2025, DSGN quarterly cash and cash equivalents is $22.56 million, with the most recent change of -$7.76 million (-25.60%) on December 1, 2024.
- Over the past year, DSGN quarterly cash and cash equivalents has dropped by -$7.76 million (-25.60%).
- DSGN quarterly cash and cash equivalents is now -94.37% below its all-time high of $400.69 million, reached on March 31, 2021.
Performance
DSGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DSGN Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +6.4% | -25.6% |
3 y3 years | -92.4% | -25.6% |
5 y5 years | +10000.0% | -25.6% |
DSGN Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -92.4% | +6.4% | -92.4% | +6.4% |
5 y | 5-year | -92.4% | >+9999.0% | -94.4% | +848.4% |
alltime | all time | -92.4% | >+9999.0% | -94.4% | +848.4% |
Design Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $22.56 M(+6.4%) | $22.56 M(-25.6%) |
Sep 2024 | - | $30.33 M(-33.6%) |
Jun 2024 | - | $45.70 M(+55.5%) |
Mar 2024 | - | $29.40 M(+38.7%) |
Dec 2023 | $21.20 M(-20.0%) | $21.20 M(-24.1%) |
Sep 2023 | - | $27.94 M(+2.7%) |
Jun 2023 | - | $27.20 M(-5.6%) |
Mar 2023 | - | $28.81 M(+8.7%) |
Dec 2022 | $26.50 M | $26.50 M(-37.7%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2022 | - | $42.52 M(-64.5%) |
Jun 2022 | - | $119.65 M(-58.4%) |
Mar 2022 | - | $287.31 M(-3.8%) |
Dec 2021 | $298.57 M(>+9900.0%) | $298.57 M(-16.5%) |
Sep 2021 | - | $357.66 M(-3.6%) |
Jun 2021 | - | $370.84 M(-7.5%) |
Mar 2021 | - | $400.69 M(>+9900.0%) |
Dec 2020 | $2.38 M(+2989.6%) | $2.38 M |
Dec 2019 | $77.00 K | - |
FAQ
- What is Design Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Design Therapeutics?
- What is Design Therapeutics annual cash & cash equivalents year-on-year change?
- What is Design Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Design Therapeutics?
- What is Design Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Design Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of DSGN is $22.56 M
What is the all time high annual cash & cash equivalents for Design Therapeutics?
Design Therapeutics all-time high annual cash & cash equivalents is $298.57 M
What is Design Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, DSGN annual cash & cash equivalents has changed by +$1.36 M (+6.43%)
What is Design Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of DSGN is $22.56 M
What is the all time high quarterly cash and cash equivalents for Design Therapeutics?
Design Therapeutics all-time high quarterly cash and cash equivalents is $400.69 M
What is Design Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, DSGN quarterly cash and cash equivalents has changed by -$7.76 M (-25.60%)